This is a working overview of amino acid substitution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-04 and is reviewed periodically as new material appears.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Two people were killed in a Russian airstrike in Zolochiv, Kharkiv Oblast. Two people were also killed in a Russian missile strike in Hirnyk, Donetsk Oblast. A missile strike on Odesa injured 14 people. In Russia, the governor of Ryazan Oblast claimed that an oil refinery was set on fire by a drone. The governor of Voronezh Oblast claimed that a drone was shot down over Voronezh city, while energy infrastructure was also damaged by drones in Kursk and Oryol Oblasts. Ukrainian special forces claimed to have disabled two Russian Buk missile systems in Sumy Oblast using attack drones. Several Russian personnel were claimed killed and equipment destroyed during a Ukrainian strike on Rohove, Luhansk Oblast. It is believed three missiles, either ATACMS or Tochka-U, were used with cluster munitions. The head of the SBU's cybersecurity unit, Illia Vitiuk, was dismissed by Zelenskyy following investigations into suspicious financial activities by the former's wife while he was in office and attempts by SBU personnel to harass journalists. The United States Department of State alleged the use of chloropicrin by Russian forces in Ukraine and imposed fresh sanctions against Russian individuals and entities as a response. Russia placed several captured and destroyed Western armored vehicles on display at Moscow, including an M1A1 Abrams, M2A2 Bradley, Leopard 2A6 and several types of lighter NATO-origin armored vehicles.
== Toxicity == The Pompilidae family of spider wasps is known for its powerful and painful sting that is used to paralyse arachnids. Social wasps readily attack any threat to their queen and colony and are the only type of insects responsible for medically significant incidents with humans. However, PMTXs are produced by solitary spider wasps and since solitary wasps do not have a colony to defend, humans normally will not be stung by these wasps. PMTX is not listed by IARC, which suggests that there is no indication of carcinogenicity for humans, other information about the effects of PMTX on humans is currently not available. However, it is thought that it won't have a big impact on humans due to the difference in neurological setup between humans and arachnids. What is known is that being stung by a spider wasp causes local pain and swelling, and some people might have an allergic reaction to the sting which can be dangerous. The symptoms of a spider wasp sting, apart from the allergic reaction, can be treated with a cold compress. Even though humans usually will not be stung by these wasps, there have been scientists that deliberately extensively provoked spider wasps similar to PMTX-producing spider wasps, to have them stung by these animals for research on the pain inflicted by these insects. Because of these individuals, it is known that though spider wasp venom causes paralysis in their arthropod prey, they inflict intense pain that remains for around five minutes onto vertebrates such as humans.
=== Skin aging research === There is also ongoing research on topical application of vitamin C to prevent signs of skin aging. Human skin physiologically contains small amounts of vitamin C, which supports collagen synthesis, decreases collagen degradation, and assists in antioxidant protection against UV-induced photo-aging, including photocarcinogenesis. This knowledge is often used as a rationale for the marketing of vitamin C as a topical "serum" ingredient to prevent or treat facial skin aging, melasma (dark pigmented spots), and wrinkles; however, these claims are unsubstantiated and are not supported by research conducted so far; the supposed efficacy of topical treatment as opposed to oral intake is poorly understood. The purported mechanism on supposed benefit of topical vitamin C application to slow skin aging is that vitamin C is an antioxidant, neutralizing free radicals from sunlight exposure, air pollutants or normal metabolic processes. The clinical trial literature is characterized as insufficient to support health claims; one reason being put forward was that "All the studies used vitamin C in combination with other ingredients or therapeutic mechanisms, thereby complicating any specific conclusions regarding the efficacy of vitamin C."
There are several pressure-lowering medication groups that could be used in lowering the IOP, usually eyedrops. The choice of medication usually depends on the dose, duration, and side effects of each medication. However, in general, prostaglandin analogues are the first-line treatment for glaucoma. Prostaglandin analogues, such as latanoprost, bimatoprost, and travoprost, reduce the IOP by increasing the aqueous fluid outflow through the draining angle. It is usually prescribed once daily at night. The systemic side effects of this class are minimal. However, they can cause local side effects, including redness of the conjunctiva, a change in the iris color, and eyelash elongation. Several other classes of medications could be used as a second-line in case of treatment failure or presence of contraindications to prostaglandin analogues. These include:
=== Epilepsy === As an adjunctive therapy in epilepsy, it is used in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. It is unclear if there are any benefits to clobazam over other seizure medications for children. It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need. Clobazam is approved in Canada (Frisium) for add-on use in tonic–clonic, complex partial, and myoclonic seizures. Clobazam is approved for adjunctive therapy in complex partial seizures, certain types of status epilepticus, specifically the myoclonic, myoclonic-absent, simple partial, complex partial, and tonic varieties, and non-status absence seizures. In the United States, clobazam (Onfi) was not marketed until October 2011 and was only approved for use in combination with other medications to control epilepsy in people aged two years of age and older who have Lennox–Gastaut syndrome.
Sources: en.wikipedia.org
=== KdV-SIR equation === Based on the classical SIR model, a Korteweg-de Vries (KdV)–SIR equation and its analytical solution have been proposed to illustrate the fundamental dynamics of an epidemic wave, the dependence of solutions on parameters, and the dependence of predictability horizons on various types of solutions. The KdV-SIR equation is written as follows:
6 September: The Tāmaki Makaurau by-election is won by Te Pāti Māori candidate Oriini Kaipara. The Sealord Group proposes closing its coated fish factory in Nelson, potentially affecting 79 jobs. 7 September – During the New Zealand First party's annual conference held at Palmerston North, party leader Winston Peters campaigns on increasing compulsory KiwiSaver contributions to ten percent and requiring migrants to sign a values statement. Pro-greyhound racing and Palestinian solidarity protesters picket the event. 8 September: Fugitive father Tom Phillips is shot dead during a confrontation with Police in Piopio, Waikato. Police take one of his children into custody and launch a search for the remaining two unaccompanied minors. By evening, police find the two remaining children safe at a remote campsite. ANZ Bank New Zealand agrees to pay a record fine of NZ$3.25 million to the New Zealand Government after admitting it had breached fair dealing laws twice between 2012 and 2023. The murder trial of Korean mother Hakyung Yee commences, who is facing murder charges for the deaths of her two children. The primary school teachers' union, the New Zealand Educational Institute, rejects the Government's latest pay offer and commences voting on strike action. 9 September – Voting commences in the 2025 local elections. 10 September – The Court of Appeal of New Zealand declines to quash Scott Watson's convictions for the murders of Ben Smart and Olivia Hope, concluding that there had been no "miscarriage of justice" in relation to the prosecution's hair evidence and Mr.
=== Injection loop === The injection loop is a segment of tubing of known volume which is filled with the sample solution before it is injected into the column. Loop volume can range from a few microliters to 50 ml or more.
=== Examples of "limiting" amino acids in plant protein === According to WHO, human need for proteins is 0.66 g per kg of bodyweight per day. A 70 kg person has an estimated protein requirement of 46.2 g (70 kg x 0.66 g/kg). In addition, there is a specific need of essential amino acids quantities. See Essential amino acid#Recommended daily intake for a table of the values; the tables below use a percentage of the requirement.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.